NecstGen

We're #hiring a new Scientist Cell Therapy in Leiden, South Holland. Apply today or share this post with your network.

Meet us in Gothenburg, Sweden, from September 4 to 6 at booth #F01.42! We will attend the ISCT Europe 2024 Regional Meeting at the Swedish Exhibition & Congress Centre. This event will gather the brightest minds in Cell and Gene Therapy, offering a deep dive into our field's latest advancements, regulatory updates, and clinical applications. The ISCT, International Society for Cell & Gene Therapy Europe 2024 Regional Meeting is a key event for professionals dedicated to pushing the boundaries of Cell and Gene Therapy. With a program full of plenary sessions, hands-on workshops, and extensive networking opportunities, it's the place to be for anyone committed to innovation and collaboration in CGT. Committed to making a difference, NecstGen operates beyond profit motives. We aim to empower therapy developers with affordable, accessible, and state-of-the-art development and manufacturing services. Will we see you in Gothenburg? Connect with our team members, Sophia Kolbe and André Soares, to discuss how we can help accelerate your project and make a lasting impact together. You can use this link to schedule a meeting: https://lnkd.in/eYJ9VA9g #iscteurope2024 #celltherapy #genetherapy #regenerativemedicine #cgts

NecstGen and biotactical, a company developing a novel rapid sterility testing approach for Cell & Gene Therapies, announce collaboration!   Sterility testing is crucial to ensure that therapies are safe for patients, but current approaches are limited if a rapid result is helpful, typically requiring up to 7 days. biotactical is devoted to solving this delay by developing a cutting-edge technology utilizing ATP-bioluminescence for ultra rapid detection of microbial contamination.   The partnership with NecstGen will help to accelerate and support biotactical’s technology allowing microbial detection to be achieved within 24 hours. NecstGen recognises the importance of new technologies that challenge the current cost and technical limitations that may limit the wider adoption of Cell and Gene Therapies.   “biotactical is delighted to collaborate with NecstGen, a Center of Excellence dedicated to bringing Cell and Gene Therapies into the clinic. We recognise this partnership as a key driver for further product development. Together, we hope to reduce the waiting time and costs for treatment for those suffering from severe diseases.”, commented Krishna Sheombar Sing, CMO and co-founder of biotactical.   NecstGen will provide access to the comprehensive expertise, technologies, and experience of its in-house Quality Control and Manufacturing teams. It will support further testing and validation of biotactical’s innovative technology for Cell and Gene Therapies. Both Leiden-based companies are eager to collaborate and exchange their knowledge to deliver the most practical solution for a real-world problem.   Paul Bilars, CEO, NecstGen highlights: “We understand biotactical’s technology has the potential to deliver results in much shorter timeframe allowing timely product release as well as early identification of contamination, which improves cost efficiency. Our partnership is entirely aligned with NecstGen’s mission to challenge technological limitations. We are proud to support the development of such a promising technology for the entire field of Cell and Gene Therapy.”   About NecstGen NecstGen is a non-profit CDMO and Centre of Excellence for Cell and Gene Therapy located in a purpose-built GMP facility in Leiden, The Netherlands. Dedicated to the field of Cell and Gene Therapies, we provide expertise and capacity to focus on patient solutions.   About biotactical biotactical is a pioneering company focused on developing rapid sterility testing solutions to accelerate the safe delivery of Cell and Gene Therapies.   #cellandgenetherapy #biotechnology #sterilitytesting #healthcareinnovation Tristan Pritchard-Meaker Justin Chotoe

Who is behind the mask? Behind those masks are dedicated professionals delivering excellence in manufacturing of Cell and Gene Therapy products. Working in a cleanroom environment requires strict adherence to gowning requirements to maintain a contaminant-free space.   At NecstGen, we are committed to advancing Cell and Gene Therapies (CGT) adhering to the highest standards of Good Manufacturing Practices (GMP). GMP ensures, that your products are consistently produced and controlled to meet rigorous quality standards. Our state-of-the-art facility and operations are designed to deliver safe and efficacious Cell and Gene Therapy products. Our team operates daily in NecstGen’s modern cleanroom facility, that can accommodate your project at every development stage. Would you like to see how these professionals work and learn more about our facilities for CGT development and manufacturing? We invite you to tour our facility and see firsthand how NecstGen can support your research and development goals. Whether you are interested in our manufacturing services or cleanroom rental, we can help you bringing therapies to patients. Contact us today to schedule your visit and explore opportunities in working with NecstGen. #lifesciences #cellandgenetherapy #cgt

We're #hiring a new Onderhoudsmonteur in Leiden, South Holland. Apply today or share this post with your network.

Have you caught the latest news in Cell and Gene Therapies? Here's an overview of recent advancements in this field:   Hemophilia A Pfizer's giroctocogene fitelparvovec, an investigational gene therapy for rare genetic bleeding disorder hemophilia A, succeeded in Phase 3 clinical trial paving the way for a potential approval. Ophthalmic Gene Therapy Beacon Therapeutics raises USD 170 million in Series B Funding to progress its pipeline of ophthalmic gene therapies focusing on both orphan and prevalent retinal diseases. https://lnkd.in/ekMyTVje Huntington's Disease uniQure's gene therapy AMT-130 has shown promising interim results in slowing the progression of Huntington's Disease. This development offers new hope for patients suffering from this debilitating neurodegenerative disorder, highlighting the potential of gene therapies in altering disease trajectories. https://lnkd.in/eDcCyCmE Bioprinted Tissue Therapeutics Aspect Biosystems announces USD 200 million partnership with the Governments of Canada and British Columbia to support multi-year project to accelerate the development of its bioprinted tissue therapeutics pipeline focusing on serious metabolic and endocrine diseases. https://lnkd.in/g6TRWgNC NK Cell Therapy Trials Artiva Biotherapeutics’ IPO jumps to USD 176 million. The NK cell therapy company plans to use the funds raised to support further development its AlloNK therapy for systemic lupus erythematosus. https://lnkd.in/eeivr3Vk SmartCella raising EUR 50 million SmartCella Holding AB announced new share issue raising EUR 50 million accelerating growth and supporting commercialisation of the Extroducer and the company’s cell and mRNA operations. Friedreich Ataxia Cardiomyopathy Lexeo Therapeutics announced positive interim Phase 1/2 clinical data of LX2006 for the treatment of Friedreich ataxia cardiomyopathy, a devastating, rare, and progressive disorder caused by loss of function mutations in the frataxin gene. https://lnkd.in/e2QD2YKA These news items are chapters that shape the story of how cell and gene therapies (CGTs) bring life-saving treatments to patients, transforming the landscape of medical care. Do you want more news like this delivered directly to your feed? Stay informed and engaged with the latest developments by following us. #celltherapy #genetherapy #CGTs #atmps

Where are most Cell and Gene Therapy developers located? The booming biotechnology sector has seen remarkable growth, particularly in Cell and Gene Therapy, which holds immense promise for meeting patients' unmet needs. With the rise of private equity investments, cross-continent acquisitions, and record-level IPOs, it's crucial to understand the geographical distribution of these innovative developers. Our goal at NecstGen is to map out these key players and hubs to provide a comprehensive overview of the industry landscape across Europe. NecstGen is proud to present the latest update to our European Cell & Gene Therapy Companies map, sharing insights into the ATMP landscape in Europe. Our updated map is more than just a visual representation of data. It's a bridge that connects major hubs and helps us understand the geographical spread of cell and gene therapy companies. By visualizing this data, we aim to foster a sense of community, support industry growth, and drive the development of next-generation therapies. Explore our map to gain valuable insights and connect with key players in the industry here: https://lnkd.in/gyJpXueh If your organization still needs to be listed, please contact us here: www.necstgen.com/contact. Together we challenge today’s possibilities and enable the unthinkable. Leiden Bio Science Park Cambridge Biomedical Campus Utrecht Science Park BioAlps - Swiss Health Valley London BioScience Innovation Centre (LBIC) Oxfordshire Local Enterprise Partnership (OxLEP) Pivot Park Amsterdam Science Park Utrecht Science Park Tech Park Basel Medicen Paris Region Lyonbiopôle Auvergne-Rhône-Alpes Institut Imagine Ideon Science Park #CGT #celltherapy #genetherapy #ATMP

What does it take to bring a cell or gene therapy to patients? Have you ever wondered what it means to develop viral vectors, cell therapies, (ex vivo) gene therapies, and more? Watch the video. Bringing a product from R&D to production takes work. When developing a cell therapy, for example, we very closely examine the processes that our client has developed so far. We go through them, identify the critical process steps, and adjust them to achieve a GMP-compliant manufacturing process. But what is the most critical aspect of it all? We operate at the edge of scientific discovery, always keeping the patient at the centre. NecstGen helps academic and industrial Cell and Gene Therapy developers enter the clinical stage by bringing together the required expertise from R&D, development, production, QA, QC, and regulatory affairs in a 4,000 m2 development and GMP manufacturing facility. Watch the video and start exploring how we bring CGTs closer to the patients who need them. #celltherapy #genetherapy #viralvector #cdmo

We are proud to share that our recurrent customer Pan Cancer T secured € 4.25 million seed extension and continues its path to the clinic to treat solid tumors! Press release: Rotterdam and Leiden, Netherlands, July 17, 2024 – NecstGen, a non-profit CDMO, and Pan Cancer T, a company developing a TCR-T cell product (PCT1:CO-STIM) for the treatment of triple negative breast cancer, announce further projects.   This new agreement with Pan Cancer T builds directly on the solid foundation established in previous collaborations between both organisations. Following a successful technology transfer and proof-of-concept scale-up, both parties are happy to announce that more activities will be performed by NecstGen at its state-of-the-art facility for Cell and Gene Therapy development and manufacturing located in Leiden.   Rachel Abbott, CEO, Pan Cancer T commented, “Successfully completing our latest funding round will accelerate our path to the clinic and treating patients. CMC development is a critical component to realising this ambition. We recognise in NecstGen a partner committed to reducing the costs of development and manufacturing whilst maintaining commitment to quality.”   The companies will continue to undertake the process and analytical development of Pan Cancer T’s novel Cell Therapy. Led by Melissa Van Pel, Head of Cell Therapy, NecstGen will utilise its large equipment portfolio and expert team to progress the process and assays required for PCT1:CO-STIM to be successfully manufactured.   This continued collaboration demonstrates NecstGen’s capability to scale and enhance processes as its partnerships evolve to enable bridging early research and clinical applications, including GMP manufacturing.    Paul Bilars, CEO, NecstGen, said, “I am delighted with my team’s performance in our partnership with Pan Cancer T to date, demonstrating what NecstGen can contribute to organisations in Cell and Gene Therapy. NecstGen now routinely receives feedback that we are offering partners a competitive cost basis. This is core to our vision as an organisation. Maximising the budget of all organisations involved in Cell and Gene Therapy will accelerate therapies reaching patients and benefiting society.” Full press release: https://lnkd.in/eYpnTgRX For more information please contact:   Pan Cancer T - Rachel Abbott, CEO NecstGen - Tristan Pritchard-Meaker, Head of Business Development